Promoted Content
Promoted Content

Find Approved Immunology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tofacitinib Citrate

            Therapeutic Area: Immunology Product Name: Xeljanz

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2020

            Details:

            With this approval XELJANZ becomes the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine

            Therapeutic Area: Immunology Product Name: Diregura

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: LTL Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 04, 2020

            Details:

            LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Upadacitinib,Methotrexate

            Therapeutic Area: Immunology Product Name: Rinvoq

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            In its guidance, NICE recommends upadacitinib, in combination with methotrexate for people with severe active RA, where their disease has responded inadequately to, or they are intolerant to at least two conventional disease-modifying anti-rheumatic drugs (DMARDs).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Upadacitinib

            Therapeutic Area: Immunology Product Name: Rinvoq

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 28, 2020

            Details:

            Presentations to highlight patient-reported outcomes of RINVOQ in patients with psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. Researchers to share updates on long-term safety & efficacy of RINVOQ for the treatment of moderate-severe RA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Upadacitinib

            Therapeutic Area: Immunology Product Name: Rinvoq

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 06, 2020

            Details:

            In SELECT-CHOICE, RINVOQ™ (upadacitinib) met both the primary and key secondary endpoints compared to ORENCIA® (abatacept) on change from baseline in DAS28-CRP at week 12 in patients with rheumatoid arthritis and inadequate response to biologic DMARDs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Upadacitinib,Methotrexate

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 04, 2020

            Details:

            Long-term results from the SELECT-COMPARE and SELECT MONOTHERAPY studies showed that RINVOQ™ (upadacitinib, 15 mg) continued to improve signs and symptoms in patients with rheumatoid arthritis through 72 and 84 weeks, respectively.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eculizumab

            Therapeutic Area: Immunology Product Name: Soliris

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: $39,000.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition December 12, 2020

            Details:

            AstraZeneca's acquisition of Alexion, with its strong commercial portfolio and robust pipeline, will support its long-term ambition to develop novel medicines in areas of immunology with high unmet medical needs.